Upjohn President Hoff resigns
Lawrence Hoff, 60, announces resignation, effective Jan. 1. Hoff's departure is part of the transition plan unveiled in November with the establishment of a five-man office of the chairman. That management group was headed by Chairman Theodore Cooper and included three newly appointed exec VPs: ex-FDA Commissioner Mark Novitch; the head of Upjohn's pharmaceutical business, Ley Smith; and the head of the consumer and chemical products, William Parfet. As scion of the Parfet family, which controls approximately 7% of Upjohn common stock, William Parfet's progress through the executive ranks is being watched closely. Cooper will assume Hoff's title as president as well as hold the chairmanship after Jan. 1. Hoff is retiring after a 40-year career spent entirely at Upjohn.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.